Search

Your search keyword '"M. Vereb"' showing total 22 results
Start Over Author "M. Vereb"
22 results on '"M. Vereb"'

1. ECG of the Month

Author

Michelle M. Vereb, Darcy B. Adin, and Monica L. Tschosik

Subjects
Electrocardiography, General Veterinary, Animals
Published
2021

2. Évolution de la demande des examens de médecine nucléaire pour cancer de la prostate depuis l’enregistrement de la fluorocholine (18F) : analyse sur deux ans à l’hôpital Tenon

Author

Virginie Huchet, Z. Idir, M. Vereb, M. Hodolic, V. Nataf, Khaldoun Kerrou, A. Kobetz, Jean-Noël Talbot, S. Balogova, F. Paycha, L. Michaud, and Françoise Montravers

Subjects
Radiological and Ultrasound Technology, Biophysics, Radiology, Nuclear Medicine and imaging
Abstract

Resume L’autorisation de mise sur le marche d’un nouveau radiopharmaceutique pour la TEP par les agences du medicament n’est pas si frequente et il a semble interessant d’en suivre les consequences sur la demande des autres examens de medecine nucleaire par les correspondants cliniciens. La fluorocholine (18F) ou FCH a ete enregistree en France le 2 avril 2010 avec parmi les indications la localisation des metastases osseuses dans le cancer de la prostate (CP). Methodes Une analyse de la demande des examens de medecine nucleaire (MN) en cas de CP a ete effectuee a l’hopital Tenon, couvrant huit trimestres depuis avril 2010. Resultats Durant ces deux ans, 721 examens de MN ont ete effectues chez des patients atteints de CP. La demande en TEP/TDM a la FCH a augmente rapidement, de 11 % des examens de MN au premier trimestre a 37 % au deuxieme trimestre et a 56 % au huitieme trimestre. Le nombre total d’examens de MN demandes pour CP a lui aussi augmente durant ces deux ans. Globalement, la part de la TEP/TDM a la FCH a ete de 42 %, celle de la TEP/TDM au fluorure (18F) de sodium (F Na) de 27 %, celle de la scintigraphie osseuse (SO) de 25 %. La demande en TEP/TDM au FDG (6 % des examens de MN) a ete limitee a quelques cas de PC hormono-resistant ou multimetastatique. Les examens limites a la detection des metastases osseuses (TEP/TDM au F Na et SO) ont ete demandes de facon tres predominante lors de la stadification initiale, alors que la FCH a ete preferee pour la detection des recidives occultes, a des concentrations bien plus faibles de PSA. Le suivi therapeutique et l’evaluation d’un traitement peu apres qu’il est termine est une indication prometteuse qui necessite une evaluation des radiopharmaceutiques ; elle a represente 19 % des examens, tout comme la restadification avant reprise d’un traitement. Conclusion La disponibilite de la TEP/TDM a la FCH aboutit a une augmentation rapide de sa demande, en particulier en cas de recidive occulte, avec une augmentation globale de la demande pour les examens de MN dans le CP, de + 11 % d’une annee sur l’autre.

Published
2012
Full Text
View/download PDF

3. Abstracts

Author

V. Dunet, A. Dabiri, G. Allenbach, A. Goyeneche Achigar, B. Waeber, F. Feihl, R. Heinzer, J. O. Prior, J. E. Van Velzen, J. D. Schuijf, F. R. De Graaf, M. A. De Graaf, M. J. Schalij, L. J. Kroft, A. De Roos, J. W. Jukema, E. E. Van Der Wall, J. J. Bax, E. Lankinen, A. Saraste, T. Noponen, R. Klen, M. Teras, T. Kokki, S. Kajander, M. Pietila, H. Ukkonen, J. Knuuti, A. P. Pazhenkottil, R. N. Nkoulou, J. R. Ghadri, B. A. Herzog, R. R. Buechel, S. M. Kuest, M. Wolfrum, O. Gaemperli, L. Husmann, P. A. Kaufmann, D. Andreini, G. Pontone, S. Mushtaq, L. Antonioli, E. Bertella, A. Formenti, S. Cortinovis, G. Ballerini, C. Fiorentini, M. Pepi, A. S. Koh, J. S. Flores, F. Y. J. Keng, R. S. Tan, T. S. J. Chua, A. D. Annoni, G. Tamborini, M. Fusari, A. L. Bartorelli, S. H. Ewe, A. C. T. Ng, V. Delgado, J. Schuijf, F. Van Der Kley, A. Colli, A. De Weger, N. A. Marsan, K. H. Yiu, A. C. Ng, S. A. J. Timmer, P. Knaapen, T. Germans, P. A. Dijkmans, M. Lubberink, J. M. Ten Berg, F. J. Ten Cate, I. K. Russel, A. A. Lammertsma, A. C. Van Rossum, Y. Y. Wong, G. Ruiter, P. Raijmakers, W. J. Van Der Laarse, N. Westerhof, A. Vonk-Noordegraaf, G. Youssef, E. Leung, G. Wisenberg, C. Marriot, K. Williams, J. Etele, R. A. Dekemp, J. Dasilva, D. Birnie, R. S. B. Beanlands, R. C. Thompson, A. H. Allam, L. S. Wann, A. H. Nureldin, G. Adelmaksoub, I. Badr, M. L. Sutherland, J. D. Sutherland, M. I. Miyamoto, G. S. Thomas, H. J. Harms, S. De Haan, M. C. Huisman, R. C. Schuit, A. D. Windhorst, C. Allaart, A. J. Einstein, T. Khawaja, C. Greer, A. Chokshi, M. Jones, K. Schaefle, K. Bhatia, D. Shimbo, P. C. Schulze, A. Srivastava, R. Chettiar, J. Moody, C. Weyman, D. Natale, W. Bruni, Y. Liu, E. Ficaro, A. J. Sinusas, A. Peix, E. Batista, L. O. Cabrera, K. Padron, L. Rodriguez, B. Sainz, V. Mendoza, R. Carrillo, Y. Fernandez, E. Mena, A. Naum, T. Bach-Gansmo, N. Kleven-Madsen, M. Biermann, B. Johnsen, J. Aase Husby, S. Rotevatn, J. E. Nordrehaug, J. Schaap, R. M. Kauling, M. C. Post, B. J. W. M. Rensing, J. F. Verzijlbergen, J. Sanchez, G. Giamouzis, N. Tziolas, P. Georgoulias, G. Karayannis, A. Chamaidi, N. Zavos, K. Koutrakis, G. Sitafidis, J. Skoularigis, F. Triposkiadis, S. Radovanovic, A. Djokovic, D. V. Simic, M. Krotin, A. Savic-Radojevic, M. Pljesa-Ercegovac, M. Zdravkovic, J. Saponjski, S. Jelic, T. Simic, R. Eckardt, B. J. Kjeldsen, L. I. Andersen, T. Haghfelt, P. Grupe, A. Johansen, B. Hesse, H. Pena, G. Cantinho, M. Wilk, Y. Srour, F. Godinho, N. Zafrir, A. Gutstein, I. Mats, A. Battler, A. Solodky, E. Sari, N. Singh, A. Vara, A. M. Peters, A. De Belder, S. Nair, N. Ryan, R. James, S. Dizdarevic, G. Depuey, M. Friedman, R. Wray, R. Old, H. Babla, B. Chuanyong, J. Maddahi, E. Tragardh Johansson, K. Sjostrand, L. Edenbrandt, S. Aguade-Bruix, G. Cuberas-Borros, M. N. Pizzi, M. Sabate-Fernandez, G. De Leon, D. Garcia-Dorado, J. Castell-Conesa, J. Candell-Riera, D. Casset-Senon, M. Edjlali-Goujon, D. Alison, A. Delhommais, P. Cosnay, C. S. Low, A. Notghi, J. O'brien, A. C. Tweddel, N. Bingham, P. O Neil, M. Harbinson, O. Lindner, W. Burchert, M. Schaefers, C. Marcassa, R. Campini, P. Calza, O. Zoccarato, A. Kisko, J. Kmec, M. Babcak, M. Vereb, M. Vytykacova, J. Cencarik, P. Gazdic, J. Stasko, A. Abreu, E. Pereira, L. Oliveira, P. Colarinha, V. Veloso, I. Enriksson, G. Proenca, P. Delgado, L. Rosario, J. Sequeira, I. Kosa, I. Vassanyi, C. S. Egyed, G. Y. Kozmann, S. Morita, M. Nanasato, I. Nanbu, Y. Yoshida, H. Hirayama, A. Allam, A. Sharef, I. Shawky, M. Farid, M. Mouden, J. P. Ottervanger, J. R. Timmer, M. J. De Boer, S. Reiffers, P. L. Jager, S. Knollema, G. M. Nasr, M. Mohy Eldin, M. Ragheb, I. Casans-Tormo, R. Diaz-Exposito, F. J. Hurtado-Mauricio, R. Ruano, M. Diego, F. Gomez-Caminero, C. Albarran, A. Martin De Arriba, A. Rosero, R. Lopez, C. Martin Luengo, J. R. Garcia-Talavera, I. E. K. Laitinen, M. Rudelius, E. Weidl, G. Henriksen, H. J. Wester, M. Schwaiger, X. B. Pan, T. Schindler, A. Quercioli, H. Zaidi, O. Ratib, J. M. Declerck, E. Alexanderson Rosas, R. Jacome, M. Jimenez-Santos, E. Romero, M. A. Pena-Cabral, A. Meave, J. Gonzalez, F. Rouzet, L. Bachelet, J. M. Alsac, M. Suzuki, L. Louedec, A. Petiet, F. Chaubet, D. Letourneur, J. B. Michel, D. Le Guludec, A. Aktas, A. Cinar, G. Yaman, T. Bahceci, K. Kavak, A. Gencoglu, A. Jimenez-Heffernan, E. Sanchez De Mora, J. Lopez-Martin, R. Lopez-Aguilar, C. Ramos, C. Salgado, A. Ortega, C. Sanchez-Gonzalez, J. Roa, A. Tobaruela, S. V. Nesterov, O. Turta, M. Maki, C. Han, D. Daou, M. Tawileh, S. O. Chamouine, C. Coaguila, E. Mariscal-Labrador, N. Kisiel-Gonzalez, P. De Araujo Goncalves, P. J. Sousa, H. Marques, J. O'neill, J. Pisco, R. Cale, J. Brito, A. Gaspar, F. P. Machado, J. Roquette, M. Martinez, G. Melendez, E. Kimura, J. M. Ochoa, A. M. Alessio, A. Patel, R. Lautamaki, F. M. Bengel, J. B. Bassingthwaighte, J. H. Caldwell, K. Rahbar, H. Seifarth, M. Schafers, L. Stegger, T. Spieker, A. Hoffmeier, D. Maintz, H. Scheld, O. Schober, M. Weckesser, H. Aoki, I. Matsunari, K. Kajinami, M. Martin Fernandez, M. Barreiro Perez, O. V. Fernandez Cimadevilla, D. Leon Duran, E. Velasco Alonso, J. P. Florez Munoz, L. H. Luyando, C. Templin, C. E. Veltman, J. H. C. Reiber, S. Venuraju, A. Yerramasu, S. Atwal, A. Lahiri, T. Kunimasa, M. Shiba, K. Ishii, J. Aikawa, E. S. J. Kroner, K. T. Ho, Q. W. Yong, K. C. Chua, C. Panknin, C. J. Roos, J. M. Van Werkhoven, A. J. Witkowska-Grzeslo, M. J. Boogers, D. V. Anand, D. Dey, D. Berman, F. Mut, R. Giubbini, L. Lusa, T. Massardo, A. Iskandrian, M. Dondi, A. Sato, Y. Kakefuda, E. Ojima, T. Adachi, A. Atsumi, T. Ishizu, Y. Seo, M. Hiroe, K. Aonuma, M. Kruk, R. Pracon, C. Kepka, J. Pregowski, A. Kowalewska, M. Pilka, M. Opolski, I. Michalowska, Z. Dzielinska, M. Demkow, V. Stoll, N. Sabharwal, A. Chakera, O. Ormerod, H. Fernandes, M. Bernardes, E. Martins, P. Oliveira, T. Vieira, G. Terroso, A. Oliveira, T. Faria, F. Ventura, J. Pereira, S. Fukuzawa, M. Inagaki, J. Sugioka, A. Ikeda, S. Okino, J. Maekawa, T. Uchiyama, N. Kamioka, S. Ichikawa, M. Afshar, R. Alvi, N. Aguilar, R. Ippili, H. Shaqra, J. Bella, N. Bhalodkar, A. Dos Santos, M. Daicz, L. O. Cendoya, H. G. Marrero, J. Casuscelli, M. Embon, G. Vera Janavel, E. Duronto, E. P. Gurfinkel, C. M. Cortes, Y. Takeishi, K. Nakajima, Y. Yamasaki, T. Nishimura, K. Hayes Brown, F. Collado, M. Alhaji, J. Green, S. Alexander, R. Vashistha, S. Jain, F. Aldaas, J. Shanes, R. Doukky, K. Ashikaga, Y. J. Akashi, M. Uemarsu, R. Kamijima, K. Yoneyama, K. Omiya, Y. Miyake, Y. Brodov, U. Raval, A. Berezin, V. Seden, E. Koretskaya, T. A. Panasenko, S. Matsuo, S. Kinuya, J. Chen, R. J. Van Bommel, B. Van Der Hiel, P. Dibbets-Schneider, E. V. Garcia, I. Rutten-Vermeltfoort, M. M. J. Gevers, B. Verhoeven, A. B. Dijk Van, E. Raaijmakers, P. G. H. M. Raijmakers, J. E. Engvall, M. Gjerde, J. De Geer, E. Olsson, P. Quick, A. Persson, M. Mazzanti, M. Marini, L. Pimpini, G. P. Perna, C. Marciano, P. Gargiulo, M. Galderisi, C. D'amore, G. Savarese, L. Casaretti, S. Paolillo, A. Cuocolo, P. Perrone Filardi, M. Al-Amoodi, E. C. Thompson, K. Kennedy, K. A. Bybee, A. I. Mcghie, J. H. O'keefe, T. M. Bateman, R. L. F. Van Der Palen, A. M. Mavinkurve-Groothuis, B. Bulten, L. Bellersen, H. W. M. Van Laarhoven, L. Kapusta, L. F. De Geus-Oei, P. P. Pollice, M. B. Bonifazi, F. P. Pollice, I. P. Clements, D. O. Hodge, C. G. Scott, M. De Ville De Goyet, B. Brichard, T. Pirotte, S. Moniotte, R. A. Tio, A. Elvan, R. A. I. O. Dierckx, R. H. J. A. Slart, T. Furuhashi, M. Moroi, H. Hase, N. Joki, H. Masai, R. Nakazato, H. Fukuda, K. Sugi, K. Kryczka, E. Kaczmarska, J. Petryka, L. Mazurkiewicz, W. Ruzyllo, P. Smanio, E. Vieira Segundo, M. Siqueira, J. Kelendjian, J. Ribeiro, J. Alaca, M. Oliveira, F. Alves, I. Peovska, J. Maksimovic, M. Vavlukis, N. Kostova, D. Pop Gorceva, V. Majstorov, M. Zdraveska, S. Hussain, M. Djearaman, E. Hoey, L. Morus, O. Erinfolami, A. Macnamara, M. P. Opolski, A. Witkowski, V. Berti, F. Ricci, R. Gallicchio, W. Acampa, G. Cerisano, C. Vigorito, R. Sciagra', A. Pupi, H. Sliem, F. M. Collado, S. Schmidt, A. Maheshwari, R. Kiriakos, V. Mwansa, S. Ljubojevic, S. Sedej, M. Holzer, G. Marsche, V. Marijanski, J. Kockskaemper, B. Pieske, A. Ricalde, G. Alexanderson, A. Mohani, P. Khanna, A. Sinusas, F. Lee, V. A. Pinas, B. L. F. Van Eck-Smit, H. J. Verberne, C. M. De Bruin, G. Guilhermina, L. Jimenez-Angeles, O. Ruiz De Jesus, O. Yanez-Suarez, E. Vallejo, E. Reyes, M. Chan, M. L. Hossen, S. R. Underwood, A. Karu, S. Bokhari, V. Pineda, L. M. Gracia-Sanchez, A. Garcia-Burillo, K. Zavadovskiy, Y. U. Lishmanov, W. Saushkin, I. Kovalev, A. Chernishov, A. Annoni, M. Tarkia, T. Saanijoki, V. Oikonen, T. Savunen, M. A. Green, M. Strandberg, A. Roivainen, M. C. Gaeta, C. Artigas, J. Deportos, L. Geraldo, A. Flotats, V. La Delfa, I. Carrio, W. J. Laarse, M. M. Izquierdo Gomez, J. Lacalzada Almeida, A. Barragan Acea, A. De La Rosa Hernandez, R. Juarez Prera, G. Blanco Palacios, J. A. Bonilla Arjona, J. J. Jimenez Rivera, J. L. Iribarren Sarrias, I. Laynez Cerdena, A. Dedic, A. Rossi, G. J. R. Ten Kate, A. Dharampal, A. Moelker, T. W. Galema, N. Mollet, P. J. De Feyter, K. Nieman, D. Trabattoni, A. Broersen, M. Frenay, M. M. Boogers, P. H. Kitslaar, J. Dijkstra, D. A. Annoni, M. Muratori, N. Johki, M. Tokue, A. S. Dharampal, A. C. Weustink, L. A. E. Neefjes, S. L. Papadopoulou, C. Chen, N. R. A. Mollet, E. H. Boersma, G. P. Krestin, J. A. Purvis, D. Sharma, S. M. Hughes, D. S. Berman, R. Taillefer, J. Udelson, M. Devine, J. Lazewatsky, G. Bhat, D. Washburn, D. Patel, T. Mazurek, S. Tandon, S. Bansal, S. Inzucchi, L. Staib, J. Davey, D. Chyun, L. Young, F. Wackers, M. T. Harbinson, G. Wells, J. Dougan, S. Borges-Neto, H. Phillips, A. Farzaneh-Far, Z. Starr, L. K. Shaw, M. Fiuzat, C. O'connor, M. Henzlova, W. L. Duvall, A. Levine, U. Baber, L. Croft, S. Sahni, S. Sethi, L. Hermann, A. Nureldin, A. Gomaa, M. A. T. Soliman, H. A. R. Hany, F. De Graaf, A. Pazhenkottil, H. M. J. Siebelink, J. H. Reiber, M. Ayub, T. Naveed, M. Azhar, A. Van Tosh, T. L. Faber, J. R. Votaw, N. Reichek, B. Pulipati, C. Palestro, K. J. Nichols, K. Okuda, Y. Kirihara, T. Ishikawa, J. Taki, M. Yoshita, M. Yamada, A. Salacata, S. Keavey, V. Chavarri, J. Mills, H. Nagaraj, P. Bhambhani, D. E. Kliner, P. Soman, J. Heo, A. E. Iskandrian, M. Jain, B. Lin, A. Walker, C. Nkonde, S. Bond, A. Baskin, J. Declerck, M. E. Soto, G. Mendoza, M. Aguilar, S. P. Williams, G. Colice, J. R. Mcardle, A. Lankford, D. K. Kajdasz, C. R. Reed, L. Angelini, F. Angelozzi, G. Ascoli, A. Jacobson, H. J. Lessig, M. C. Gerson, M. D. Cerqueira, J. Narula, M. Uematsu, K. Kida, K. Suzuki, P. E. Bravo, K. Fukushima, M. Chaudhry, J. Merrill, A. Alonso Tello, J. F. Rodriguez Palomares, G. Marti Aguasca, S. Aguade Bruix, V. Aliaga, P. Mahia, T. Gonzalez-Alujas, J. Candell, A. Evangelista, R. Mlynarski, A. Mlynarska, M. Sosnowski, B. Zerahn, P. Hasbak, C. E. Mortensen, H. F. Mathiesen, M. Andersson, D. Nielsen, L. Ferreira Santos, M. J. Ferreira, D. Ramos, D. Moreira, M. J. Cunha, A. Albuquerque, A. Moreira, J. Oliveira Santos, G. Costa, L. A. Providencia, Y. Arita, S. Kihara, N. Mitsusada, M. Miyawaki, H. Ueda, H. Hiraoka, Y. Matsuzawa, J. Askew, M. O'connor, L. Jordan, R. Ruter, R. Gibbons, T. Miller, L. Emmett, A. Ng, N. Sorensen, R. Mansberg, L. Kritharides, T. Gonzalez, H. Majmundar, N. P. Coats, S. Vernotico, J. H. Doan, T. M. Hernandez, M. Evini, A. D. Hepner, T. K. Ip, W. A. Chalela, A. M. Falcao, L. O. Azouri, J. A. F. Ramires, J. C. Meneghetti, F. Manganelli, M. Spadafora, P. Varrella, G. Peluso, R. Sauro, E. Di Lorenzo, F. Rotondi, S. Daniele, P. Miletto, A. J. M. Rijnders, B. W. Hendrickx, W. Van Der Bruggen, Y. G. C. J. America, P. J. Thorley, F. U. Chowdhury, C. J. Dickinson, S. I. Sazonova, I. Y. U. Proskokova, A. M. Gusakova, S. M. Minin, Y. U. B. Lishmanov, V. V. Saushkin, G. Rodriguez, F. Roffe, H. Ilarraza, D. Bialostozky, A. N. Kitsiou, P. Arsenos, I. Tsiantis, S. Charizopoulos, S. Karas, R. C. Vidal Perez, M. Garrido, V. Pubul, S. Argibay, C. Pena, M. Pombo, A. B. Ciobotaru, A. Sanchez-Salmon, A. Ruibal Morell, J. R. Gonzalez-Juanatey, E. Rodriguez-Gomez, B. Martinez, D. Pontillo, F. Benvissuto, F. Fiore Melacrinis, S. Maccafeo, E. V. Scabbia, R. Schiavo, Y. Golzar, C. Gidea, J. Golzar, D. Pop-Gorceva, M. Zdravkovska, S. Stojanovski, L. J. Georgievska-Ismail, T. Katsikis, A. Theodorakos, A. Kouzoumi, M. Koutelou, Y. Yoshimura, T. Toyama, H. Hoshizaki, S. Ohshima, M. Inoue, T. Suzuki, A. Uitterdijk, M. Dijkshoorn, M. Van Straten, W. J. Van Der Giessen, D. J. Duncker, D. Merkus, G. Platsch, J. Sunderland, C. Tonge, P. Arumugam, T. Dey, H. Wieczorek, R. Bippus, R. L. Romijn, B. E. Backus, T. Aach, M. Lomsky, L. Johansson, J. Marving, S. Svensson, J. L. Pou, F. P. Esteves, P. Raggi, R. Folks, Z. Keidar, J. W. Askew, L. Verdes, L. Campos, V. Gulyaev, A. Pankova, J. Santos, S. Carmona, I. Henriksson, A. Prata, M. Carrageta, A. I. Santos, K. Yoshinaga, M. Naya, C. Katoh, O. Manabe, S. Yamada, H. Iwano, S. Chiba, H. Tsutsui, N. Tamaki, I. Vassiliadis, E. Despotopoulos, O. Kaitozis, E. Hatzistamatiou, R. Thompson, J. Hatch, M. Zink, B. S. Gu, G. D. Bae, C. M. Dae, G. H. Min, E. J. Chun, S. I. Choi, M. Al-Mallah, K. Kassem, O. Khawaja, D. Goodman, D. Lipkin, L. Christiaens, B. Bonnet, J. Mergy, D. Coisne, J. Allal, N. Dias Ferreira, D. Leite, J. Rocha, M. Carvalho, D. Caeiro, N. Bettencourt, P. Braga, V. Gama Ribeiro, U. S. Kristoffersen, A. M. Lebech, H. Gutte, R. S. Ripa, N. Wiinberg, C. L. Petersen, G. Jensen, A. Kjaer, C. Bai, R. Conwell, R. D. Folks, L. Verdes-Moreiras, D. Manatunga, A. F. Jacobson, D. Belzer, Y. Hasid, M. Rehling, R. H. Poulsen, L. Falborg, J. T. Rasmussen, L. N. Waehrens, C. W. Heegaard, J. M. U. Silvola, S. Forsback, J. O. Laine, S. Heinonen, S. Ylaherttuala, A. Broisat, M. Ruiz, N. C. Goodman, J. Dimastromatteo, D. K. Glover, F. Hyafil, F. Blackwell, G. Pavon-Djavid, L. Sarda-Mantel, L. J. Feldman, A. Meddahi-Pelle, V. Tsatkin, Y.- H. Liu, R. De Kemp, P. J. Slomka, R. Klein, G. Germano, R. S. Beanlands, A. Rohani, V. Akbari, J. G. J. Groothuis, M. Fransen, A. M. Beek, S. L. Brinckman, M. R. Meijerink, M. B. M. Hofman, C. Van Kuijk, S. Kogure, E. Yamashita, J. Murakami, R. Kawaguchi, H. Adachi, S. Oshima, S. Minin, S. Popov, Y. U. Saushkina, G. Savenkova, D. Lebedev, E. Alexandridis, D. Rovithis, C. Parisis, I. Sazonova, V. Saushkin, V. Chernov, L. Zaabar, H. Bahri, S. Hadj Ali, A. Sellem, I. Slim, N. El Kadri, H. Slimen, H. Hammami, S. Lucic, A. Peter, S. Tadic, K. Nikoletic, R. Jung, M. Lucic, K. Tagil, D. Jakobsson, S.- E. Svensson, P. Wollmer, L. Leccisotti, L. Indovina, L. Paraggio, M. L. Calcagni, A. Giordano, M. Kapitan, A. Paolino, M. Nunez, J. Sweeny, N. Kulkarni, K. Guma, Y. Akashi, M. Takano, M. Takai, S. Koh, F. Miyake, N. Torun, G. Durmus Altun, A. Altun, E. Kaya, H. Saglam, D. T. Matsuoka, A. Sanchez, C. Bartolozzi, D. Padua, G. Ponta, A. Ponte, A. Carneiro, A. Thom, R. Ashrafi, P. Garg, G. Davis, A. Falcao, M. Costa, F. Bussolini, J. A. C. Meneghetti, M. Tobisaka, E. Correia, J. W. Jansen, P. A. Van Der Vleuten, T. P. Willems, F. Zijlstra, M. Sato, K. Taniguchi, M. Kurabayashi, D. Pop Gjorcheva, M. Zdraveska-Kochovska, K. Moriwaki, A. Kawamura, K. Watanabe, T. Omura, S. Sakabe, T. Seko, A. Kasai, M. Ito, M. Obana, T. Akasaka, C. Hruska, D. Truong, C. Pletta, D. Collins, C. Tortorelli, D. Rhodes, M. El-Prince, A. Martinez-Moeller, M. Marinelli, S. Weismueller, C. Hillerer, B. Jensen, S. G. Nekolla, H. Wakabayashi, K. Tsukamoto, S. M. E. A. Baker, K. M. H. S. Sirajul Haque, A. Siddique, S. Krishna Banarjee, A. Ahsan, F. Rahman, M. Mukhlesur Rahman, T. Parveen, M. Lutfinnessa, F. Nasreen, H. Sano, S. Naito, M. L. De Rimini, G. Borrelli, F. Baldascino, P. Calabro, C. Maiello, A. Russo, C. Amarelli, P. Muto, I. Danad, P. G. Raijmakers, Y. E. Appelman, O. S. Hoekstra, J. T. Marcus, A. Boonstra, D. V. Ryzhkova, T. V. Kuzmina, O. S. Borodina, M. A. Trukshina, I. S. Kostina, H. Hommel, G. Feuchtner, O. Pachinger, G. Friedrich, A. M. Stel, J. W. Deckers, V. Gama, A. Ciarka, L. A. Neefjes, N. R. Mollet, E. J. Sijbrands, J. Wilczek, C. Llibre Pallares, O. Abdul-Jawad Altisent, H. Cuellar Calabria, P. Mahia Casado, M. T. Gonzalez-Alujas, A. Evangelista Masip, D. Garcia-Dorado Garcia, Y. Tekabe, X. Shen, Q. Li, J. Luma, D. Weisenberger, A. M. Schmidt, R. Haubner, L. Johnson, L. Sleiman, S. Thorn, M. Hasu, M. Thabet, J. N. Dasilva, S. C. Whitman, D. Genovesi, A. Giorgetti, A. Gimelli, G. Cannizzaro, F. Bertagna, G. Fagioli, M. Rossi, R. Bonini, P. Marzullo, C. A. Paterson, S. A. Smith, A. D. Small, N. E. R. Goodfield, W. Martin, S. Nekolla, H. Sherif, S. Reder, M. Yu, A. Kusch, D. Li, J. Zou, M. S. Lloyd, K. Cao, D. W. Motherwell, A. Rice, G. M. Mccurrach, S. M. Cobbe, M. C. Petrie, I. Al Younis, E. Van Der Wall, T. Mirza, M. Raza, H. Hashemizadeh, L. Santos, B. A. Krishna, F. Perna, M. Lago, M. Leo, G. Pelargonio, G. Bencardino, M. L. Narducci, M. Casella, F. Bellocci, S. Kirac, O. Yaylali, M. Serteser, T. Yaylali, A. Okizaki, Y. Urano, M. Nakayama, S. Ishitoya, J. Sato, Y. Ishikawa, M. Sakaguchi, N. Nakagami, T. Aburano, S. V. Solav, R. Bhandari, S. Burrell, S. Dorbala, I. Bruno, C. Caldarella, A. Collarino, M. V. Mattoli, A. Stefanelli, A. Cannarile, F. Maggi, V. Soukhov, S. Bondarev, A. Yalfimov, M. Khan, P. P. Priyadharshan, G. Chandok, T. Aziz, M. Avison, R. A. Smith, D. S. Bulugahapitya, T. Vakhtangadze, F. Todua, M. Baramia, G. Antelava, N.- C. Roche, P. Paule, S. Kerebel, J.- M. Gil, L. Fourcade, A. Tzonevska, K. Tzvetkov, M. Atanasova, V. Parvanova, A. Chakarova, E. Piperkova, B. Kocabas, H. Muderrisoglu, C. P. Allaart, E. Entok, S. Simsek, B. Akcay, I. Ak, E. Vardareli, M. Stachura, P. J. Kwasiborski, G. J. Horszczaruk, E. Komar, A. Cwetsch, B. Zraik, R. Morales Demori, A. D. J. Almeida, M. E. Siqueira, E. Vieira, I. Balogh, G. Kerecsen, E. Marosi, Z. S. Szelid, A. Sattar, T. Swadia, J. Chattahi, W. Qureshi, F. Khalid, A. Gonzalez, S. Hechavarria, K. Takamura, S. Fujimoto, R. Nakanishi, S. Yamashina, A. Namiki, J. Yamazaki, K. Koshino, Y. Hashikawa, N. Teramoto, M. Hikake, S. Ishikane, T. Ikeda, H. Iida, Y. Takahashi, N. Oriuchi, H. Higashino, K. Endo, T. Mochizuki, K. Murase, A. Baali, R. Moreno, M. Chau, H. Rousseau, F. Nicoud, P. Dolliner, L. Brammen, G. Steurer, T. Traub-Weidinger, P. Ubl, P. Schaffarich, G. Dobrozemsky, A. Staudenherz, M. Ozgen Kiratli, B. Temelli, N. B. Kanat, T. Aksoy, G. A. Slavich, G. Piccoli, M. Puppato, S. Grillone, D. Gasparini, S. Perruchoud, C. Poitry-Yamate, M. Lepore, R. Gruetter, T. Pedrazzini, D. Anselm, A. Anselm, H. Atkins, J. Renaud, R. Dekemp, I. Burwash, A. Guo, R. Beanlands, C. Glover, I. Vilardi, B. Zangheri, L. Calabrese, P. Romano, A. Bruno, O. C. Fernandez Cimadevilla, V. A. Uusitalo, M. Luotolahti, M. Wendelin-Saarenhovi, J. Sundell, O. Raitakari, S. Huidu, R. Gadiraju, M. Ghesani, Q. Uddin, B. Wosnitzer, N. Takahashi, E. Alhaj, A. Legasto, B. Abiri, K. Elsaban, T. El Khouly, T. El Kammash, A. Al Ghamdi, B. Kyung Deok, K. Bon Seung, Y. Sang Geun, D. Chang Min, and M. Gwan Hong

Subjects
Cardiology and Cardiovascular Medicine
Published
2011
Full Text
View/download PDF

4. 18F-fluorocholine may be taken-up by brown adipose tissue

Author

L. Michaud, V. Huchet, M. Vereb, Khaldoun Kerrou, L. Fartoux, O. Rosmorduc, Françoise Montravers, S. Balogova, Pierre Decazes, and J.-N. Talbot

Subjects
Adenoma, Adult, Pathology, medicine.medical_specialty, business.industry, Liver Neoplasms, Adipose tissue, General Medicine, White adipose tissue, Choline, Diagnosis, Differential, medicine.anatomical_structure, Adipose Tissue, Brown, Fluorodeoxyglucose F18, Positron-Emission Tomography, Brown adipose tissue, Medicine, Humans, Radiology, Nuclear Medicine and imaging, False Positive Reactions, Female, Radiopharmaceuticals, business, Artifacts, 18F-fluorocholine
Published
2012

5. Oral Abstract session * Non invasive evaluation of coronary artery disease: 12/12/2013, 14:00-15:30 * Location: Bursa

Author

A. Kisko, M. Vereb, M. Barreiro Perez, M. Martin Fernandez, O. Cimadevilla Fernandez, A. Renilla Gonzalez, E. Diaz Pelaez, J. Rozado Castano, P. Dobson, P. Cai, P. Leung, K. Marshall, M. Albarjas, T. Rogers, J. Hill, K. Alfakih, A. Cai, S. Basu, D. Andreini, G. Pontone, S. Mushtaq, E. Bertella, E. Conte, A. Baggiano, A. Annoni, A. Formenti, C. Fiorentini, and M. Pepi

Subjects
medicine.medical_specialty, business.industry, Gated SPECT, Ischemia, General Medicine, medicine.disease, Lesion, Coronary artery disease, Stenosis, medicine.anatomical_structure, medicine, Radiology, Nuclear Medicine and imaging, Radiology, Myocardial infarction, medicine.symptom, Cardiology and Cardiovascular Medicine, business, Perfusion, Artery
Abstract

Coronary angiography has diagnostic limitation in identifying non-stenotic coronary lesion (NSCL) responsible for ischemia. Myocardial perfusion defects in patients (pts) with NSCL have often been unreasonably considered by invasive cardiologists as being "false positive". We evaluated a prognostic value of gated SPECT MPI in unselected group of the pts with NSCL over a 24 month period of follow-up. 170 pts (115 males, 67.6%; age 42-68 years; mean age 56.4+9.2 years) with NSCL (stenosis of 50% or less of LAD and 70% or less of any other coronary artery or its major branches) were enrolled into the study. Retrospective analysis of 86 pts with NSCL and subsequent positive MPS performed within 6 months from the time of coronary angiography (study group) and 84 pts with normal scan results (control group) was performed. Follow-up period was for24 months fromthe timeof MPIor up to the time ofmajor coronary event (MCE) first occurrence of cardiac death or myocardial infarction. Over a two-year follow-up, approximately 11% of the pts in study group had MCE as compared to 3.2% in the control group (P , .01). Abnormal MPI, EF , 35% and high levels of hs-CRP were independent predictors for MCE in the study group. In multivariate analysis only an abnormal MPI remained to be an independent predictor regardless of size or severity of perfusion abnormalities (P ,.005). Pts with NSCL on coronary angiography and myocardial perfusion defects have relatively highevent rate (11%) ofMCE overaperiodof24months fromthe timeofMPI. So,wehighly recommend gated SPECT MPI to be obligatory performed in all cases of NSCL to avoid life-threatening coronary complications in forthcoming future.

Published
2013
Full Text
View/download PDF

7. Absence of DAZ gene mutations in cases of non-obstructed azoospermia

Author

Colin E. Bishop, J T Houston, L I Lipschultz, Alexander I. Agulnik, Dolores J. Lamb, and M Vereb

Subjects
Male, Embryology, Sequence analysis, Molecular Sequence Data, Biology, Gene mutation, Y chromosome, medicine.disease_cause, Sequence-tagged site, Y Chromosome, Genetics, medicine, Humans, Molecular Biology, Gene, Azoospermia, Mutation, Base Sequence, Genome, Human, Point mutation, Obstetrics and Gynecology, RNA-Binding Proteins, Cell Biology, Deleted in Azoospermia 1 Protein, Oligospermia, Sequence Analysis, DNA, medicine.disease, Reproductive Medicine, Developmental Biology
Abstract

Sequenced-tagged site (STS) analysis of the Y chromosome long arm (Yq) of azoospermic males has identified a minimum common deleted region of several hundred kilobases in approximately 13% of cases. A candidate azoospermia gene, DAZ (deleted in azoospermia), has been isolated from this region. DAZ has also been shown to be absent in severely oligozoospermic males albeit at a much lower frequency. These data, although highly suggestive, do not constitute formal proof that DAZ actually plays a role in azoospermia, as no small intragenic deletions, rearrangements or point mutations in the gene have been found. In this study we report the screening of DNA from 168 azoospermic/oligospermic males for the presence of the DAZ gene. Deletions involving DAZ were detected in five out of 43 (11.6%) azoospermic males whereas none were found in the remaining 125 oligospermic patients. We present the genomic structure of the 5' end of the DAZ gene together with its sequence analysis in 30 non-obstructed azoospermic males. No mutations in DAZ were found in any of the patients sequenced. These data provide no formal proof that DAZ is AZF. Thus the possibility is still valid that another gene(s) mapping to the deletion interval may be responsible for, or contribute to, the observed phenotypes. Alternatively, if DAZ is AZF, they suggest that the most frequent cause of gene inactivation is via large deletions possibly mobilized by Y chromosome repetitive sequences.

Published
1997

8. EVALUATION OF MICROVASCULAR CORONARY LESION IN HYPERTENSIVES WITH LEFT VENTRICULAR HYPERTROPHY AND ISCHEMIC-LIKE ST SEGMENT CHANGES

Author

J. Kmec, J. Cencarik, M. Babcak, P. Gazdic, A. Kisko, J. Stasko, M. Vereb, and M. Vytykacova

Subjects
medicine.medical_specialty, Physiology, business.industry, Left ventricular hypertrophy, medicine.disease, Lesion, Internal medicine, Internal Medicine, Cardiology, Medicine, ST segment, medicine.symptom, Cardiology and Cardiovascular Medicine, business
Published
2011
Full Text
View/download PDF

11. Efficacy of a mitral regurgitation severity index to predict long-term outcome in dogs with myxomatous mitral valve disease.

Author

Vereb M, Atkins CE, Adin D, Blondel T, Coffman M, Lee S, Guillot E, and Ward JL

Subjects
Humans, Dogs, Animals, Mitral Valve, Retrospective Studies, Mitral Valve Insufficiency diagnostic imaging, Mitral Valve Insufficiency veterinary, Dog Diseases diagnostic imaging, Heart Valve Diseases veterinary, Heart Failure diagnostic imaging, Heart Failure veterinary
Abstract

Background: Predicting progression of myxomatous mitral valve disease (MMVD) in dogs can be challenging., Hypothesis/objectives: The mitral regurgitation severity index (MRSI) will predict time to congestive heart failure (CHF) and all-cause death in dogs with MMVD., Animals: Eight hundred sixty-nine client-owned dogs., Methods: Retrospective study pooling data from 4 previous samples including dogs with MMVD stage B2 or C. MRSI was calculated as: (heart rate [HR]/120) × left atrium-to-aorta ratio (LA:Ao) × (age in years/10) × 100. Alternative MRSI formulas substituting radiographic measures of left atrial size were also calculated. Cox proportional hazard modeling and time-dependent receiver-operator characteristic curves quantified prognostic performance., Results: For Stage B2 pooled samples, MRSI > 156 was predictive of time to CHF (median 407 vs 1404 days; area under the curve [AUC] 0.68; hazard ratio 3.02 [95% CI 1.9-4.9]; P < .001). MRSI > 173 was predictive of all-cause death (median survival 868 vs 1843 days; AUC 0.64; hazard ratio 4.26 [95% CI 2.4-7.5]; P < .001). MRSI showed superior predictive value compared to the individual variables of HR, LA:Ao, and age. Variations of the MRSI equation substituting radiographic vertebral left atrial size for LA:Ao were also significantly predictive of outcome in stage B2. MRSI was not consistently predictive of outcome in Stage C., Conclusions and Clinical Importance: MRSI was predictive of outcome (onset of CHF and all-cause death) in MMVD Stage B2, demonstrating utility as a useful prognostic tool. Echocardiographic LA:Ao can be effectively replaced by radiographically determined LA size in the MRSI formula., (© 2023 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.)

Published
2024
Full Text
View/download PDF

12. [Pain reduction by radiosynoviorthesis in rheumatism-induced synovitis of the elbow : Results of a retrospective multicenter data analysis].

Author

Freudenberg LS, Baraliakos X, Kampen WU, Vereb M, Fischer M, Toenshoff G, Boddenberg-Pätzold B, Czech N, and Klett R

Subjects
Humans, Radioisotopes adverse effects, Elbow, Treatment Outcome, Pain diagnosis, Pain etiology, Pain radiotherapy, Elbow Joint, Synovitis diagnosis, Synovitis radiotherapy, Rheumatic Diseases drug therapy, Arthritis, Rheumatoid complications, Arthritis, Rheumatoid diagnosis, Arthritis, Rheumatoid radiotherapy, Collagen Diseases drug therapy
Abstract

Background: Radiosynoviorthesis (RSO) is a nuclear medical local treatment modality for inflammatory joint diseases. It is indicated in patients with rheumatoid arthritis (RA) in joints with persistent synovitis despite adequate pharmacotherapy. Arthritis of the elbow joint occurs in up to 2/3 of patients with RA. Intra-articular radiotherapy using the beta emitter [ 186 Re] rhenium sulfide leads to sclerosis of the inflamed synovial membrane with subsequent pain alleviation. The clinical efficacy in cubital arthritis, however, has so far only been described in small monocentric studies., Objective: The degree of pain alleviation by RSO was analyzed in patients with rheumatoid cubital arthritis, treated in several nuclear medical practices specialized in RSO., Material and Methods: The subjective pain intensity before and after RSO was documented in a total of 107 patients with rheumatic cubital arthritis using a 10-step numeric rating scale (NRS). A difference of ≥ -2 is rated as a significant improvement. Follow-up examinations were done after a mean interval of 14 months after RSO (at least 3 months, maximum 50 months)., Results: The mean NRS value was 7.3 ± 2.1 before RSO and 2.8 ± 2.2 after RSO. A significant pain alleviation was seen in 78.5% of all patients treated. The subgroup analysis also showed a significant improvement in the pain symptoms in all groups depending on the time interval between the RSO and the control examination. A significant pain progression was not observed. The degree of pain relief was independent of the time of follow-up., Conclusion: Using RSO for local treatment of rheumatoid cubital arthritis leads to a significant and long-lasting pain relief in more than ¾ of the treated patients., (© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)

Published
2023
Full Text
View/download PDF

13. Effect of diet change in healthy dogs with subclinical cardiac biomarker or echocardiographic abnormalities.

Author

Haimovitz D, Vereb M, Freeman L, Goldberg R, Lessard D, Rush J, and Adin D

Subjects
Animals, Biomarkers, Diet veterinary, Dogs, Peptide Fragments, Prospective Studies, Troponin I, Echocardiography veterinary, Natriuretic Peptide, Brain
Abstract

Background: A recent study showed higher high-sensitivity cardiac troponin I (hs-cTnI) concentrations in healthy dogs eating grain-free (GF) compared to those eating grain-inclusive (GI) diets., Hypothesis/objectives: Healthy dogs with subclinical cardiac abnormalities eating GF diets at baseline will show improvements in cardiac biomarkers and echocardiographic variables after diet change, whereas healthy dogs eating GI diets at baseline will not improve., Animals: Twenty healthy dogs with subclinical cardiac abnormalities (12 Golden Retrievers, 5 Doberman Pinschers, 3 Miniature Schnauzers)., Methods: This prospective study included dogs with increased hs-cTnI or N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations, or echocardiographic abnormalities. Mixed modeling was used to evaluate echocardiographic, hs-cTnI, and NT-proBNP differences between groups (GF or GI diet at baseline) over time (1 y after diet change)., Results: Ten GF and 10 GI dogs were evaluated. There were statistically significant time: group interactions for hs-cTnI (P = .02) and normalized left ventricular internal systolic diameter (LVIDsN; P = .02), with GF dogs showing larger decreases in these variables than GI dogs. Median (range) hs-cTnI (ng/mL) for GF dogs was 0.141 (0.012-0.224) at baseline and 0.092 (0.044-0.137) at 1 y, and for GI dogs was 0.051 (0.016-0.195) at baseline and 0.060 (0.022-0.280) at 1 y. Median LVIDsN for GF dogs was 1.01 (0.70-1.30) at baseline and 0.87 (0.79-1.24) at 1 y, and for GI dogs was 1.05 (0.84-1.21) at baseline and 1.10 (0.85-1.28) at 1 y., Conclusions and Clinical Importance: Decreased hs-cTnI and LVIDsN in GF dogs after diet change supports reversibility of these subclinical myocardial abnormalities., (© 2022 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.)

Published
2022
Full Text
View/download PDF

14. Prospective study of dilated cardiomyopathy in dogs eating nontraditional or traditional diets and in dogs with subclinical cardiac abnormalities.

Author

Freeman L, Rush J, Adin D, Weeks K, Antoon K, Brethel S, Cunningham S, Santos LD, Girens R, Goldberg R, Karlin E, Lessard D, Lopez K, Rouben C, Vereb M, and Yang V

Subjects
Animals, Diet veterinary, Dogs, Echocardiography veterinary, Prospective Studies, Cardiomyopathy, Dilated veterinary, Dog Diseases
Abstract

Background: Recent studies have investigated dogs with presumed diet-associated dilated cardiomyopathy (daDCM), but prospective studies of multiple breeds are needed., Hypothesis/objectives: To evaluate baseline features and serial changes in echocardiography and cardiac biomarkers in dogs with DCM eating nontraditional diets (NTDs) or traditional diets (TDs), and in dogs with subclinical cardiac abnormalities (SCA) eating NTD., Animals: Sixty dogs with DCM (NTD, n = 51; TDs, n = 9) and 16 dogs with SCA eating NTDs., Methods: Echocardiography, electrocardiography, and measurement of taurine, cardiac troponin I, and N-terminal pro-B-type natriuretic peptide were performed in dogs with DCM or SCA. Diets were changed for all dogs, taurine was supplemented in most, and echocardiography and cardiac biomarkers were reassessed (3, 6, and 9 months)., Results: At enrollment, there were few differences between dogs with DCM eating NTDs or TDs; none had low plasma or whole blood taurine concentrations. Improvement in fractional shortening over time was significantly associated with previous consumption of a NTD, even after adjustment for other variables (P = .005). Median survival time for dogs with DCM was 611 days (range, 2-940 days) for the NTD group and 161 days (range, 12-669 days) for the TD group (P = .21). Sudden death was the most common cause of death in both diet groups. Dogs with SCA also had significant echocardiographic improvements over time., Conclusions and Clinical Importance: Dogs with DCM or SCA previously eating NTDs had small, yet significant improvements in echocardiographic parameters after diet changes., (© 2022 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.)

Published
2022
Full Text
View/download PDF

15. Effect of type of diet on blood and plasma taurine concentrations, cardiac biomarkers, and echocardiograms in 4 dog breeds.

Author

Adin D, Freeman L, Stepien R, Rush JE, Tjostheim S, Kellihan H, Aherne M, Vereb M, and Goldberg R

Subjects
Animals, Biomarkers, Cross-Sectional Studies, Diet veterinary, Dogs, Echocardiography veterinary, Natriuretic Peptide, Brain, Peptide Fragments, Plant Breeding, Dog Diseases diagnostic imaging, Taurine
Abstract

Background: Associations of diet with dilated cardiomyopathy are under investigation., Objectives: That cardiac assessment would show abnormalities in healthy dogs eating grain-free (GF) diets or diets with Food and Drug Administration (FDA)-listed ingredients of concern (peas, lentils, or potatoes) as top 10 ingredients (FDA-PLP), but not in dogs eating grain-inclusive (GI) diets or diets without FDA-listed ingredients of concern (PLP) in the top 10 ingredients (NoFDA-PLP)., Animals: One hundred eighty-eight healthy Doberman Pinschers, Golden Retrievers, Miniature Schnauzers, and Whippets., Methods: This study was an observational cross-sectional study. Echocardiograms, cardiac biomarkers, and blood and plasma taurine concentrations were compared between dogs eating GF (n = 26) and GI (n = 162) diets, and between FDA-PLP (n = 39) and NoFDA-PLP (n = 149) diets, controlling for age and breed. Demographic characteristics, murmurs, genetic status, and ventricular premature complexes (VPCs) during examination were compared between dogs eating different diet types., Results: No differences in echocardiographic variables, N-terminal pro-B-type natriuretic peptide or whole blood taurine were noted between dogs eating different diet types. Dogs eating GF diets had higher median high-sensitivity cardiac troponin I (hs-cTnI) (GF 0.076 ng/mL [Interquartile range (IQR), 0.028-0.156] vs. GI 0.048 [IQR, 0.0026-0.080]; P < .001) and higher median plasma taurine (GF 125 nmol/mL [IQR, 101-148] vs GI 104 [IQR, 86-123]; P = .02) than dogs eating GI diets. Dogs eating FDA-PLP diets had higher median hs-cTnI (0.059 ng/mL [IQR, 0.028-0.122]) than dogs eating NoFDA-PLP diets (0.048 [IQR, 0.025-0.085]; P = .006). A greater proportion of dogs eating FDA-PLP diets (10%) had VPCs than dogs eating NoFDA-PLP diets (2%; P = .04)., Conclusions and Clinical Importance: Higher hs-cTnI in healthy dogs eating GF and FDA-PLP diets might indicate low-level cardiomyocyte injury., (© 2021 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.)

Published
2021
Full Text
View/download PDF

16. Radiosynoviorthesis of acromioclavicular joint using 169Er-citrate: prospective evaluation of efficacy.

Author

Vereb M, Liepe K, Fischer M, Kaliska L, Noskovicova L, and Balogova S

Subjects
Adult, Aged, Aged, 80 and over, Beta Particles adverse effects, Beta Particles therapeutic use, Erbium adverse effects, Female, Humans, Male, Middle Aged, Prospective Studies, Radioisotopes adverse effects, Safety, Acromioclavicular Joint radiation effects, Arthritis, Rheumatoid radiotherapy, Citric Acid therapeutic use, Erbium therapeutic use, Radioisotopes therapeutic use
Abstract

Background: There is a clinical need for therapeutic alternative in patients with persisting painful arthritis of AC-joint and failure of previous treatments. However, no radiopharmaceutical is currently explicitly approved for radiosynoviorthesis of acromioclavicular joint. The aim of our study was to prospectively assess the efficacy and safety of radiosynoviorthesis of acromioclavicular joint using erbium-169 citrate., Material and Methods: Radiosynoviorthesis of acromioclavicular joint was performed in 51 consecutive patients (18 males, 33 females) mean age 64.3 (range 43.8-82.6, median 63.6) years with clinically confirmed arthritis of 85 acromioclavicular joints. The efficacy of RSO was reported by patients according to 10-step visual analogue scale of pain (VAS) (0 = no pain, 10 = most severe pain) at 6 months after radiosynoviorthesis and by ranking the global therapeutic effect of RSO in 4 categories (1 = the best effect, 4 = no change). To assess the variation of blood perfusion in treated joints, the efficacy of RSO was also evaluated by variation of target (acromioclavicular joint)/non-target (soft tissue) uptake ratio (T/NTR) of metylendiphosphonate (99mTc) measured as number of counts over region of interest on blood pool phase of two-phase bone scintigraphy performed before and 6 months after RSO., Results: Radiosynoviorthesis was followed by significant decrease in VAS, mean - 3.1 (-47%). Excellent, good, moderate and bad response was observed in 57 (67%), 25 (29%), 1 (1%) and in 2 (2%) of acromioclavicular joints respectively. A significant correlation between decrease of T/NTR and variation of VAS in % (ρ = 0.532, p < 0.0001) and between T/NTR and subjective evaluation of therapeutic effect in scale 1-4 (ρ = 0.388, p = 0.0002) was observed. However, it was not possible to identify the cut-off value of relative decrease in T/NTR showing sufficient sensitivity and specificity to detect the therapeutic response., Conclusion: Results of this prospective study permit to conclude a good efficacy and safety of radiosynoviorthesis using erbium-169 citrate in a series of patients with arthritis of acromioclavicular joint in whom previous line(s) of treatment did not lead to satisfactory pain relief.

Published
2018
Full Text
View/download PDF

17. Consequence of the introduction of routine FCH PET/CT imaging for patients with prostate cancer: a dual centre survey.

Author

Hodolic M, Michaud L, Huchet V, Balogova S, Nataf V, Kerrou K, Vereb M, Fettich J, and Talbot JN

Abstract

Background: Fluorocholine(18F) (FCH) was introduced at the beginning of April 2010 in France, Slovenia and three other EU member states for the localisation of bone metastases of prostate cancer with PET. The aim of the study was to compare the evolution of diagnostic imaging in patients with prostate cancer using a new radiopharmaceutical FCH, observed in France and in Slovenia, and to quantify the consequence of the results of new imaging modality on the detection rate of abnormal metastases and recurrences of prostate cancer., Patients and Methods: In two centres (France/Slovenia), a survey of the number of nuclear medicine examinations in patients with prostate cancer was performed, covering 5 quarters of the year since the introduction of FCH. For each examination, the clinical and biological circumstances were recorded, as well as the detection of bone or soft tissue foci., Results: Six hundred and eighty-eight nuclear medicine examinations were performed impatients with prostate cancer. Nuclear medicine examinations were performed for therapy monitoring and follow-up in 23% of cases. The number of FCH PET/CT grew rapidly between the 1(st) and 5(th) period of the observation (+220%), while the number of bone scintigraphies (BS) and fluoride(18F) PET/CTs decreased (-42% and -23% respectively). Fluorodeoxyglucose(18F) (FDG) PET/CT remained limited to few cases of castrate-resistant or metastatic prostate cancer in Paris. The proportion of negative results was significantly lower with FCH PET/CT (14%) than with BS (49%) or fluoride(18F) PET/CT (54%). For bone metastases, the detection rate was similar, but FCH PET/CT was performed on average at lower prostate-specific antigen (PSA) levels and was less frequently doubtful (4% vs. 28% for BS). FCH PET/CT also showed foci in prostatic bed (53% of cases) or in soft tissue (35% of cases)., Conclusions: A rapid development of FCH PET/CT was observed in both centres and led to a higher detection rate of prostate cancer lesions.

Published
2014
Full Text
View/download PDF

18. What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma?

Author

Slavikova K, Montravers F, Treglia G, Kunikowska J, Kaliska L, Vereb M, Talbot JN, and Balogova S

Subjects
Amines metabolism, Blood Glucose metabolism, Bone and Bones diagnostic imaging, Carcinoma, Neuroendocrine, Dihydroxyphenylalanine analogs & derivatives, Fluorine Radioisotopes, Fluorodeoxyglucose F18, Humans, Multimodal Imaging economics, Neoplasm Recurrence, Local economics, Positron-Emission Tomography economics, Radiation Dosage, Receptors, Somatostatin metabolism, Thyroid Neoplasms economics, Tomography, X-Ray Computed economics, Multimodal Imaging methods, Neoplasm Recurrence, Local diagnostic imaging, Positron-Emission Tomography methods, Radiopharmaceuticals economics, Thyroid Neoplasms diagnostic imaging, Tomography, X-Ray Computed methods
Abstract

Among thyroid malignancies, medullary thyroid carcinoma (MTC) has some very specific features. Production and secretion of large amounts of peptides occur in malignant transformed C cells with few exceptions, leading to high serum levels of calcitonin (Ctn) and carcinoembryonic antigen (CEA), that act after thyroidectomy as tumour markers warning for the presence of persistent or metastatic MTC. The availability of those serum biomarkers with an excellent sensitivity challenges medical imaging to localise the recurrent cancer tissue, since surgery is a major therapeutic option. The aims of this article are (i) to review literature evidence about the efficacy and tolerance of radiopharmaceuticals for 3 targets of PET/CT imaging (glucose metabolism, bioamines metabolism and somatostatin receptors) and also bone scintigraphy which is recommended in the Guidelines of European Society for Medical Oncology (ESMO; (ii) to compare the availability and the costs in relation with those radiopharmaceuticals, (iii) and to discuss a possible sequence of those examinations, in order to optimise spending and to minimise the overall radiation dose. In this context of recurrent MTC suspected on rising tumour markers levels after thyroidectomy, this survey of literature confirms that FDOPA is the best radiopharmaceutical for PET/CT with significant diagnostic performance if Ctn>150 pg/mL; an early image acquisition starting during the first 15 min is advised. In negative cases, FDG should be the next PET radiopharmaceutical, in particular if Ctn and CEA levels are rapidly rising, and PET with a somatostatin analogue labelled with gallium-68 when neither FDOPA nor FDG PET are conclusive. Bone scintigraphy could complement FDG-PET/CT if FDOPA is not available.

Published
2013
Full Text
View/download PDF

19. 18F-fluorocholine may be taken-up by brown adipose tissue.

Author

Balogova S, Michaud L, Vereb M, Decazes P, Huchet V, Kerrou K, Fartoux L, Montravers F, Rosmorduc O, and Talbot JN

Subjects
Adenoma diagnostic imaging, Adenoma metabolism, Adult, Choline pharmacokinetics, Diagnosis, Differential, False Positive Reactions, Female, Fluorodeoxyglucose F18 pharmacokinetics, Humans, Liver Neoplasms diagnostic imaging, Liver Neoplasms metabolism, Radiopharmaceuticals pharmacokinetics, Adipose Tissue, Brown diagnostic imaging, Adipose Tissue, Brown metabolism, Artifacts, Choline analogs & derivatives, Positron-Emission Tomography methods
Published
2013

20. Ectopic parathyroid adenoma with Tc-99m MIBI washout: role of SPECT.

Author

Khan MS, Khan S, Vereb M, Al-Nahhas AM, Dina R, Lynn J, and Fleming W

Subjects
Adenoma metabolism, Adenoma surgery, Aged, Choristoma metabolism, Female, Humans, Metabolic Clearance Rate, Parathyroid Neoplasms metabolism, Parathyroid Neoplasms surgery, Radiopharmaceuticals pharmacokinetics, Tomography, Emission-Computed, Single-Photon methods, Adenoma diagnostic imaging, Choristoma diagnostic imaging, Parathyroid Glands, Parathyroid Neoplasms diagnostic imaging, Technetium Tc 99m Sestamibi pharmacokinetics
Abstract

The authors present a case of a 71-year-old woman with clinical and biochemical features of primary hyperparathyroidism and a history of right pneumonectomy. An ultrasound scan did not demonstrate any abnormality. A planar Tc-99m methoxyisobutylisonitrile (Tc-99m MIBI) scan showed an area of minimally increased uptake within the right hemithorax. However, unlike most adenomas, this demonstrated washout similar to the thyroid at 90 minutes and 3 hours. Subsequent SPECT imaging clearly showed the lesion in the superior right hemithorax. A CT scan and angiogram confirmed the presence of this mass. After surgery, histology confirmed the diagnosis of a parathyroid adenoma. Postoperatively, the calcium and PTH levels returned to normal.

Published
2006
Full Text
View/download PDF

21. Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer.

Author

Guay AT, Perez JB, Fitaihi WA, and Vereb M

Subjects
Administration, Cutaneous, Adult, Aged, Clomiphene pharmacology, Humans, Injections, Intramuscular, Luteinizing Hormone blood, Male, Middle Aged, Prolactin blood, Prostate pathology, Prostatic Neoplasms pathology, Retrospective Studies, Risk Assessment, Testosterone administration & dosage, Testosterone blood, Hypogonadism drug therapy, Prostate-Specific Antigen blood, Prostatic Neoplasms blood, Testosterone therapeutic use
Abstract

Objective: To assess prostate-specific antigen (PSA) levels in hypogonadal men after testosterone replacement by three different methods and attempt to determine any possible relationship between hypogonadism and prostate cancer in this study population., Methods: A total of 90 consecutive men who had erectile dysfunction and were found to have hypogonadism were monitored with digital rectal examination (DRE) and measurement of PSA levels before and after testosterone replacement therapy. The patients were treated with one of three options: (1) testosterone enanthate by intramuscular injections, 200 or 300 mg every 2 or 3 weeks (N = 25); (2) testosterone nonscrotal patches, 5 mg daily (N = 16); or (3) clomiphene citrate, 50 mg orally three times a week, in patients with functional secondary hypogonadism (N = 49). Treatment was continued for 2 to 3 months, after which PSA levels were reassessed. Patients with suspicious results on DRE and increased PSA levels before or after treatment with testosterone underwent prostate biopsy. For statistical analysis, patients were categorized into two age-groups--40 to 60 years old and 61 to 80 years old., Results: With all methods of testosterone replacement, PSA levels increased in both age-groups. Endogenous testosterone elevation from clomiphene stimulation raised PSA levels the highest, and testosterone patches yielded the least PSA response. Ten men underwent biopsy of the prostate. In one patient, a nodule was found on DRE; the other nine men underwent biopsy because of suspicious PSA levels. Of these patients, two were found to have adenocarcinoma, and a third man who underwent rebiopsy was also found to have cancer. Therefore, 3 of the 90 patients (3.3%) had prostate cancer., Conclusions: PSA levels increased in response to all types of testosterone replacement, regardless of whether the testosterone level was raised endogenously or exogenously. PSA levels are inappropriately low in hypogonadal men and may mask an underlying cancer. Determining PSA levels before and after testosterone treatment is recommended. Elevated PSA levels before or after testosterone therapy should prompt performance of a urologic evaluation for possible prostate biopsy.

Published
2000
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results